{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:52:38Z","timestamp":1792093958395,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute for Health Research Capability Fund"},{"DOI":"10.13039\/100007534","name":"B. Braun","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007534","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to investigate long-term survival of paclitaxel DCB for percutaneous coronary intervention (PCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Safety concerns have been raised over the use of paclitaxel devices for peripheral artery disease recently, following a meta-analysis suggesting increased late mortality. With regard to drug-coated balloon (DCB) angioplasty for coronary artery intervention however, there is limited data to date regarding possible late mortality relating to paclitaxel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared all-cause mortality of patients treated with paclitaxel DCB to those with non-paclitaxel second-generation drug-eluting stents (DES) for stable, de novo coronary artery disease from 1st January 2011 till 31st December 2018. To have homogenous groups allowing data on safety to be interpreted accurately, we excluded patients with previous PCI and patients treated with a combination of both DCB and DES in subsequent PCIs. Data were analysed with Kaplan\u2013Meier curves and Cox regression statistical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We present 1517 patients; 429 treated with paclitaxel DCB and 1088 treated with DES. On univariate analysis, age, hypercholesterolaemia, hypertension, peripheral vascular disease, prior myocardial infarction, heart failure, smoking, atrial fibrillation, decreasing estimated glomerular filtration rate (eGFR) [and renal failure (eGFR\u2009&lt;\u200945)] were associated with worse survival. DCB intervention showed a non-significant trend towards better prognosis compared to DES (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08). On multivariable analysis age, decreasing eGFR and smoking associated with worse prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We found no evidence of late mortality associated with DCB angioplasty compared with non-paclitaxel second-generation DES in up to 5 years follow-up. DCB is a safe option for the treatment of de novo coronary artery disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-020-01734-6","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T10:04:34Z","timestamp":1599041074000},"page":"220-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-0357","authenticated-orcid":false,"given":"Ioannis","family":"Merinopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharusha","family":"Gunawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upul","family":"Wickramarachchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Maart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulfi","family":"Sreekumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Sawh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Wistow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toomas","family":"Sarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisdair","family":"Ryding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Perperoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios S.","family":"Vassiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Eccleshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"1734_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrcardio.2013.165","volume":"11","author":"R Byrne","year":"2014","unstructured":"Byrne R, Joner M, Alfonso F et al (2014) Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol 11:13\u201323. https:\/\/doi.org\/10.1038\/nrcardio.2013.165","journal-title":"Nat Rev Cardiol"},{"key":"1734_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01679-w","author":"G Rigatelli","year":"2020","unstructured":"Rigatelli G, Zuin M, Nikolov P et al (2020) One- and 3-year outcomes of percutaneous bifurcation left main revascularization with modern drug-eluting stents: a systematic review and meta-analysis. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-020-01679-w","journal-title":"Clin Res Cardiol"},{"key":"1734_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01612-1","author":"JT Neumann","year":"2020","unstructured":"Neumann JT, Go\u00dfling A, S\u00f6rensen NA et al (2020) Temporal trends in incidence and outcome of acute coronary syndrome. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-020-01612-1","journal-title":"Clin Res Cardiol"},{"key":"1734_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00392-018-1328-x","volume":"107","author":"R Colleran","year":"2018","unstructured":"Colleran R, Kastrati A (2018) Percutaneous coronary intervention: balloons, stents and scaffolds. Clin Res Cardiol 107:55\u201363. https:\/\/doi.org\/10.1007\/s00392-018-1328-x","journal-title":"Clin Res Cardiol"},{"key":"1734_CR5","first-page":"1","volume":"6736","author":"RV Jeger","year":"2018","unstructured":"Jeger RV, Farah A, Ohlow M et al (2018) Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet 6736:1\u20138","journal-title":"Lancet"},{"key":"1734_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0140-6736(19)31126-2","volume":"6736","author":"TT Rissanen","year":"2019","unstructured":"Rissanen TT, Uskela S, Er\u00e4nen J et al (2019) Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet 6736:1\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(19)31126-2","journal-title":"Lancet"},{"key":"1734_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jcin.2019.04.016","volume":"9","author":"NS Vos","year":"2019","unstructured":"Vos NS, Fagel ND, Amoroso G et al (2019) Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction. JACC Cardiovasc Interv 9:1691\u20131699. https:\/\/doi.org\/10.1016\/j.jcin.2019.04.016","journal-title":"JACC Cardiovasc Interv"},{"key":"1734_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01603-2","author":"G Fahrni","year":"2020","unstructured":"Fahrni G, Scheller B, Coslovsky M et al (2020) Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-020-01603-2","journal-title":"Clin Res Cardiol"},{"key":"1734_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00392-018-1346-8","volume":"108","author":"X Yu","year":"2019","unstructured":"Yu X, Ji F, Xu F et al (2019) Treatment of large de novo coronary lesions with paclitaxel-coated balloon only: results from a Chinese institute. Clin Res Cardiol 108:234\u2013243. https:\/\/doi.org\/10.1007\/s00392-018-1346-8","journal-title":"Clin Res Cardiol"},{"key":"1734_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jcin.2018.11.040","volume":"12","author":"RM Ali","year":"2019","unstructured":"Ali RM, Abdul Kader MASK, Wan Ahmad WA et al (2019) Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. JACC Cardiovasc Interv 12:558\u2013566. https:\/\/doi.org\/10.1016\/j.jcin.2018.11.040","journal-title":"JACC Cardiovasc Interv"},{"key":"1734_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jcin.2018.12.034","volume":"12","author":"B Cortese","year":"2019","unstructured":"Cortese B (2019) Sirolimus-coated balloons: a Ferrari for our coronary patients or another elegant town car? JACC Cardiovasc Interv 12:567\u2013568. https:\/\/doi.org\/10.1016\/j.jcin.2018.12.034","journal-title":"JACC Cardiovasc Interv"},{"key":"1734_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.011245","author":"K Katsanos","year":"2018","unstructured":"Katsanos K, Kitrou P, Karnabatidis D et al (2018) Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.118.011245","journal-title":"J Am Heart Assoc"},{"key":"1734_CR13","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.jacc.2019.01.013","volume":"73","author":"PA Schneider","year":"2019","unstructured":"Schneider PA, Laird JR, Doros G et al (2019) Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol 73:2550\u20132563. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.013","journal-title":"J Am Coll Cardiol"},{"key":"1734_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00270-019-02194-w","volume":"42","author":"T Albrecht","year":"2019","unstructured":"Albrecht T, Schnorr B, Kutschera M et al (2019) Two-year mortality after angioplasty of the femoro-popliteal artery with uncoated balloons and paclitaxel-coated balloons\u2014a pooled analysis of four randomized controlled multicenter trials. Cardiovasc Intervent Radiol 42:949\u2013955. https:\/\/doi.org\/10.1007\/s00270-019-02194-w","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1734_CR15","unstructured":"FDA. UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality. 2019.https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/August-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel. Accessed 28 Oct 2019"},{"key":"1734_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/circinterventions.109.873703","volume":"2","author":"R Waksman","year":"2009","unstructured":"Waksman R, Pakala R (2009) Drug-eluting balloon: The comeback kid? Circ Cardiovasc Interv 2:352\u2013358. https:\/\/doi.org\/10.1161\/circinterventions.109.873703","journal-title":"Circ Cardiovasc Interv"},{"key":"1734_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy394","author":"M Sousa-Uva","year":"2018","unstructured":"Sousa-Uva M, Ahlsson A, Alfonso F et al (2018) 2018 ESC\/EACTS Guidelines on myocardial revascularization The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of th. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehy394","journal-title":"Eur Heart J"},{"key":"1734_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/s0140-6736(19)31126-2","volume":"394","author":"TT Rissanen","year":"2019","unstructured":"Rissanen TT, Uskela S, Er\u00e4nen J et al (2019) Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet 394:230\u2013239. https:\/\/doi.org\/10.1016\/s0140-6736(19)31126-2","journal-title":"Lancet"},{"key":"1734_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz594","author":"D Giacoppo","year":"2019","unstructured":"Giacoppo D, Alfonso F, Xu B et al (2019) Paclitaxel-coated balloon angioplasty vs drug-eluting stenting for the treatment of coronary in-stent restenosis : a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz594","journal-title":"Eur Heart J"},{"key":"1734_CR20","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jacc.2019.11.065","volume":"75","author":"B Scheller","year":"2020","unstructured":"Scheller B, Vukadinovic D, Jeger R et al (2020) Survival after coronary revascularization with paclitaxel-coated balloons. J Am Coll Cardiol 75:1017\u20131028. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.065","journal-title":"J Am Coll Cardiol"},{"key":"1734_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1161\/circulationaha.119.041099","volume":"140","author":"JA Beckman","year":"2019","unstructured":"Beckman JA, White CJ (2019) Paclitaxel-coated balloons and eluting stents: is there a mortality risk in patients with peripheral artery disease? Circulation 140:1342\u20131351. https:\/\/doi.org\/10.1161\/circulationaha.119.041099","journal-title":"Circulation"},{"key":"1734_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jvs.2019.05.002","volume":"70","author":"JL Mills","year":"2019","unstructured":"Mills JL, Conte MS, Murad MH (2019) Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease. J Vasc Surg 70:3\u20137. https:\/\/doi.org\/10.1016\/j.jvs.2019.05.002","journal-title":"J Vasc Surg"},{"key":"1734_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ejvs.2019.01.030","volume":"57","author":"A Saratzis","year":"2019","unstructured":"Saratzis A, Mani K, Zayed H (2019) Paclitaxel eluting endovascular technology and long-term mortality: safety concern or a reminder of an obvious literature gap? Eur J Vasc Endovasc Surg 57:327\u2013328. https:\/\/doi.org\/10.1016\/j.ejvs.2019.01.030","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"1734_CR24","unstructured":"Ludman PF. BCIS Audit returns adult interventional procedures. 2019.http:\/\/www.bcis.org.uk\/wp-content\/uploads\/2019\/02\/BCIS-Audit-2017-18-data-for-web-ALL-excl-TAVI-as-27-02-2019.pdf. Accessed 28 Oct 2019."}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-020-01734-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:58:21Z","timestamp":1630526301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-020-01734-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01734-6","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"VSV received honoraria for speaking at conferences by Daiichi-Sankyo and Novartis. SCE received research grants and lecture honoraria from B Braun and lecture honoraria from Boston Scientific. The other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Northwest Haydock research ethics committee and institutional approval from the Norfolk & Norwich University Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not deemed necessary according to Confidentiality Advisory Group (17\/CAG\/0145).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}